Abstract
Susceptibility to metronidazole of 213 clinical strains of H. pylori from dyspeptic patients was determined by a plate dilution method. Seventy two (33.8%) of the strains were resistant to metronidazole (MIC > 8 mg/L), 20 of these were from 24 patients who had received previously metronidazole (83.3%), giving a primary (pretreatment) resistance rate of 27.5% (52/189). The resistance rate was higher in women than in men, especially aged 50 to 59 years old (43.6% vs 23.3%, p < 0.001). The resistance rate was lower in patients at 60 or over (9.8%), but similar between the younger patients groups (38.8% - 49.0%). There was no difference in the resistance rate between peptic ulcer disease (32.6%) and nonulcer dyspepsia (34.7%). These data indicated that metronidazole resistance in H. pylori is absolutely associated with previous use of the drug, and the higher resistance rate in women may be due to the more frequent prescription of the drug for their gynaecological infection or operation. Therefore, testing of susceptibility of H. pylori to metronidazole is important. A new susceptibility testing technique, the E-test was evaluated in this study and found to give comparable results to the plate dilution method and also had the advantage of being simple to perform.
MeSH Terms
Adolescent
Adult
Aged
Aged, 80 and over
Child
Drug Resistance, Microbial
Dyspepsia/drug therapy,microbiology
Female
Helicobacter Infections/complications,drug therapy
Helicobacter pylori/drug effects
Humans
Male
Metronidazole/pharmacology,therapeutic use
Microbial Sensitivity Tests
Middle Aged
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Xia H X
Department of Clinical Microbiology, St. James's Hospital, Dublin, Ireland.
Daw M A
Beattie S
Keane C T
O'Morain C A
References (12)
12 references, click to expand
-
Helicobacter pylori infection treated with a tripotassium dicitrato bismuthate and metronidazole combination.
Aliment Pharmacol Ther. 1990 Dec;4(6):651-7
PMID: 2129652
-
Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance.
Aliment Pharmacol Ther. 1992 Aug;6(4):427-35
PMID: 1420735
-
Role of metronidazole resistance in therapy of Helicobacter pylori infections.
Antimicrob Agents Chemother. 1992 Jan;36(1):163-6
PMID: 1590683
-
The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis.
J Antimicrob Chemother. 1986 Mar;17(3):309-14
PMID: 3700291
-
Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria.
J Clin Microbiol. 1991 Mar;29(3):533-8
PMID: 2037671
-
Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies.
J Clin Pathol. 1988 Feb;41(2):207-10
PMID: 3280609
-
Metronidazole resistance in Helicobacter pylori.
Lancet. 1990 Apr 21;335(8695):976-7
PMID: 1970050
-
Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori.
Lancet. 1988 Dec 24-31;2(8626-8627):1437-42
PMID: 2904568
-
Metronidazole-resistant Helicobacter pylori.
Lancet. 1990 Mar 3;335(8688):539-40
PMID: 1968548
-
Helicobacter pylori and duodenal ulcer recurrence.
Am J Gastroenterol. 1992 Jan;87(1):24-7
PMID: 1728120
-
In vitro activity of metronidazole against Helicobacter pylori as determined by agar dilution and agar diffusion.
Antimicrob Agents Chemother. 1991 Jun;35(6):1230-1
PMID: 1929268
-
Cure of duodenal ulcer associated with eradication of Helicobacter pylori.
Lancet. 1990 May 26;335(8700):1233-5
PMID: 1971318